via Wikipedia
Clears the Way for Drug Development for Skeletal Muscle Diseases
A researcher at the University of Houston College of Pharmacy has identified the proteins necessary for efficient regeneration of skeletal muscles after acute injury and in Duchenne Muscular Dystrophy (DMD). Ashok Kumar, Else and Philip Hargrove Endowed Professor of Pharmacological and Pharmaceutical Sciences, is reporting his findings in eLife.
Skeletal muscles, which connect your bones and allow you to move, contain 50-75% of all the body’s proteins. Not only are they the most abundant and dynamic tissue of the human body essential for posture, locomotion and breathing, but they also control the body’s entire metabolism.
So, when skeletal muscles get hurt or injured either through trauma or degenerative disease, it can become complicated.
“We identified that the IRE1 protein – localized on the membrane of endoplasmic reticulum (the organelle that is involved in the production, folding and quality control of proteins) and XBP1 protein are important for efficient regeneration of skeletal muscle after injury and in DMD,” reports Kumar. Anirban Roy, research assistant professor of pharmacology, is the paper’s first author.
Understanding the mechanisms of skeletal muscle regeneration is essential for the development of new therapeutics aimed at treating various genetic and acquired degenerative muscle disorders.
“We found that skeletal muscle repair was considerably diminished in models in which IRE1 or XBP1 protein was specifically removed from skeletal muscle. These proteins support skeletal muscle regeneration through enhancing the proliferation of resident muscle stem cells. Deletion of IRE1 in skeletal muscle reduces abundance of muscle stem cells and exaggerates muscular dystrophy phenotype,” said Kumar.
Ongoing studies in the Kumar laboratory are investigating whether recently developed highly specific pharmacological activators of IRE1 and XBP1 can improve skeletal muscle regeneration after acute injury and other muscle degenerative diseases.
“The research work has enormous scope for drug development for skeletal muscle diseases,” said Kumar.
Original Article: Breakthrough Identification of Proteins Necessary for Muscle Regeneration
More from: University of Houston
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Regeneration of skeletal muscles
- New study reveals the key role of mitochondrial proteins in cardiac regeneration
Mitochondria play an essential role in supplying the energy needed for correct cell function. Within mitochondria, energy production is generated by the respiratory chain, which is formed of five ...
- A CNIC study reveals the key role of mitochondrial proteins in cardiac regeneration
CNIC study reveals the crucial role of Cox7a1 protein family in mitochondrial function, impacting cellular energy production and cardiac regeneration ...
- Harnessing Myokines To Preserve Muscle Power As We Age
Muscles are the engine of the body. But with age, we begin to lose muscle mass, leading to frailty and reduced mobility. Proteins called myokines may provide a solution.
- Our body doesn’t want to get old, shows first human muscle map
These included for example increased regeneration of remaining fiber ... “With these insights into healthy skeletal muscle aging, researchers worldwide can explore ways to combat inflammation ...
- Human muscle map reveals how we try to fight effects of ageing
This impairs the cells’ ability to repair and regenerate muscle fibres as we age. Further, non-muscle cell populations within these skeletal muscle samples produced more of a pro-inflammatory ...
Go deeper with Google Headlines on:
Regeneration of skeletal muscles
[google_news title=”” keyword=”regeneration of skeletal muscles” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Drug development for skeletal muscle diseases
- Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 ...
- Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
Fulcrum entered an exclusive global license deal with GSK for rights to the oral small-molecule drug losmapimod in April 2019.
- Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
The deal gives the pharma partial rights to a medicine GSK once developed for heart disease but could soon become the first therapy for facioscapulohumeral muscular dystrophy.
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
Based on its current operating plans, Fulcrum now expects that its cash, cash equivalents, and marketable securities as of March 31, 2024, together with the $80.0 million upfront payment to be ...
- Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
Edgewise reveals strong cash position and progressing clinical-stage programs, sparking a bull run. Find out why this is a good time to sell EWTX stock.
Go deeper with Google Headlines on:
Drug development for skeletal muscle diseases
[google_news title=”” keyword=”drug development for skeletal muscle diseases” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]